Stewart Mann recounts the highlights of several ESC sessions in which the Universal Definition of MI Task Force discussed the deliberations behind their latest version.
This week’s topics include studies on biolimus-eluting stents vs. bare-metal stents, risk markers to improve CV event prediction, common carotid intima-media thickness and CV risk prediction, aspirin with alteplase for acute ischemic stroke, and lipid-lowering therapy (and its benefits and harms) in patients with CKD.
A meta-analysis about lipid-modifying therapies and risk for pancreatitis focuses on a benefit of statins but de-emphasizes potential harm from fibrates.
Eric Topol says it’s time to “get rid of the randomized trial.” What do you say?
A highly anticipated study analyzing failures of St. Jude Durata and Riata ST Optim ICD leads has been published online in Europace by prominent electrophysiologist and ICD critic Dr. Robert Hauser along with associates from the Minneapolis Heart Institute. Over the past year St. Jude Medical has been beset with bad news about its ICD leads. Until recently, the criticism was confined to the older-generation Riata and Riata ST leads. These leads have been shown to be prone to both structural and electrical failures at an increased rate compared with competitive… Continue Reading
Recent articles in the diabetes literature might provide more evidence about editorial standards than about glycemic control.
This week’s topics include studies on the benefits of drug-eluting vs. bare-metal stents, using walking speed and blood pressure measurements to predict mortality in the elderly, stroke and bleeding in AF with chronic kidney disease, and the diagnosis and management of peripheral artery disease.
Kevin Lomangino asks why the curator of PubMed continues to index Reviews in Cardiovascular Medicine after the journal engaged in questionable editorial practices that promote commercial interests.
Dr. Samuel Gidding responds to a recent post by Dr. James Stein about the value of universal lipid screening for children age 9 to 11 years.
This week’s topics include using existing data for new research; normal weight, diabetes, and non-CVD death; cholesterol levels in U.S. kids; statins and diabetes; HDL-C and MI protection; statin treatment; hypertension treatment; clopidogrel and PPIs; and an analysis behind the “innovation crisis” of the pharmaceutical industry.
